Compare iShares Core High Dividend ETF (HDV) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Heron Therapeutics Inc — how do they compare? iShares Core High Dividend ETF trades at $28.71 (market cap $14.68B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: iShares Core High Dividend ETF is far larger — about 215.9× Heron Therapeutics Inc's market cap, and iShares Core High Dividend ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Heron Therapeutics Inc for 35 Days on average.
| HDV | HRTX | |
|---|---|---|
Market Cap | $14.68B | $68.01M |
Volume | 2,925,562 | 1,891,941 |
52-Week High | $29.93 | $1.49 |
52-Week Low | $23.64 | $0.27 |
Typical Hold Time | 117 Days | 35 Days |
Sector | — | Health |
Enterprise Value | — | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.82, up 1.91% today, with bullish technical signals from moving averages and oscillators. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure while increasing energy, staples, and utilities, resulting in heightened concentration risk with 62% allocation to three sectors. Recent dividend payments of $0.06-$0.10 per share demonstrate consistent income generation despite the strategic shift.
The ETF's 3% yield faces scrutiny for potentially insufficient compensation given increased concentration risk. While technical momentum remains positive, fundamental concerns about sector allocation and yield adequacy warrant careful monitoring. The combination of bullish technical indicators with fundamental repositioning creates a mixed outlook requiring balanced risk assessment.
Heron Therapeutics (HRTX) trades at $0.36, down 8.15% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish technical setup and institutional confidence contrast with persistent losses and negative cash flow from operations. Investors face upside from potential operational improvements against the risk of continued financial underperformance in the competitive biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
